हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Charlotte Frances Dundas Doran, Peggy Miller
Aim: Diffuse Tenosynovial Giant Cell Tumour (TGCT) formerly recognized under the synonym Pigmented Villonodular Synovitis (PVNS), is a proliferative, locally destructive, benign synovial tumour. Which most commonly affects monoarticular weight bearing joints. This disease often results in a debilitating functional impairment for the patient, early osteoarthritis, coupled with a tenacious recurrence rate. Current treatment options include early synovectomy, radiation therapy and colony stimulating factor-one (CSF-1) inhibitor Pexidartinib. However, there is a dearth of treatment protocols and management can prove difficult. The purpose of this study was to systematically review the most recent treatment methods of TGCT affecting weight bearing knee, hip, and ankle joints.
Methods: A systematic review of literature was carried out in July 2021. Keywords included “Treatment Options” and “Diffuse Tenosynovial Giant Cell Tumour.” The authors then examined 194 articles of which 36 articles were selected and read.
Study design: Review of Literature, level of evidence IV.
Results: 36 articles were selected.
Conclusion: It is apparent diffuse TGCT has the potential to cause severe functional impairment for the patient. A combination approach utilizing both surgical and systemic treatment modalities appear the current best clinical practice against this obdurate tumour.